Home Healthcare Pharmaceuticals Pemetrexed Market

Pemetrexed Market Size, Share & Trends Analysis Report By Application (Malignant Pleural Mesothelioma, Non-Squamous NSCLC), By End-User (Hospitals, Oncology Centers, Online Pharmacies, Offline Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format: | Report Code: SR206DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Pemetrexed Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Malignant Pleural Mesothelioma
    2. Non-Squamous NSCLC
  2. Pemetrexed Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Oncology Centers
    3. Online Pharmacies
    4. Offline Pharmacies
  3. Regional Pemetrexed Market
    1. North America
      1. North America Pemetrexed Market By Application 2022-2034 (USD MILLION/ Units)
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
      2. North America Pemetrexed Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Online Pharmacies
        4. Offline Pharmacies
      3. U.S.
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      4. Canada
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
    2. Europe
      1. Europe Pemetrexed Market By Application 2022-2034 (USD MILLION/ Units)
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
      2. Europe Pemetrexed Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Online Pharmacies
        4. Offline Pharmacies
      3. U.K.
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      4. Germany
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      5. France
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      6. Spain
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      7. Italy
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      8. Russia
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      9. Nordic
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      10. Benelux
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      11. Rest of Europe
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
    3. APAC
      1. APAC Pemetrexed Market By Application 2022-2034 (USD MILLION/ Units)
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
      2. APAC Pemetrexed Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Online Pharmacies
        4. Offline Pharmacies
      3. China
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      4. Korea
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      5. Japan
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      6. India
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      7. Australia
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      8. Taiwan
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      9. South East Asia
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      10. Rest of Asia-Pacific
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
    4. Middle East and Africa
      1. Middle East and Africa Pemetrexed Market By Application 2022-2034 (USD MILLION/ Units)
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
      2. Middle East and Africa Pemetrexed Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Online Pharmacies
        4. Offline Pharmacies
      3. UAE
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      4. Turkey
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      5. Saudi Arabia
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      6. South Africa
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      7. Egypt
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      8. Nigeria
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      9. Rest of MEA
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
    5. LATAM
      1. LATAM Pemetrexed Market By Application 2022-2034 (USD MILLION/ Units)
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
      2. LATAM Pemetrexed Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Online Pharmacies
        4. Offline Pharmacies
      3. Brazil
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      4. Mexico
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      5. Argentina
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      6. Chile
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      7. Colombia
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
      8. Rest of LATAM
        1. Malignant Pleural Mesothelioma
        2. Non-Squamous NSCLC
        3. Hospitals
        4. Oncology Centers
        5. Online Pharmacies
        6. Offline Pharmacies
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.